SCHEMBL1680674

SCHEMBL1680674

C(=CC1CC1)c1cccs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
ALDH1A1 P00352 3/20 0.41
PTGS1 P23219 2/20 0.40
ABCB11 O95342 1/20 0.40
CHRM2 P08172 1/20 0.40
MAOA P21397 1/20 0.40
ACHE P22303 1/20 0.40
CYP1A1 P04798 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP1B1 Q16678 2/20 0.40
ALOX5 P09917 1/20 0.40
PTGS2 P35354 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.39
NR1I2 O75469 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22763881 1.00 HCAR2 (0.46) HCAR2SMN1; SMN2RAB9ANPC1POLB
SCHEMBL1680673 1.00 HCAR2 (0.46) HCAR2SMN1; SMN2RAB9ANPC1POLB
SCHEMBL1801877 0.77 HCAR2 (0.60) HCAR2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL12018827 0.77 HCAR2 (0.60) HCAR2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL3089611 0.77 HCAR2 (0.60) HCAR2SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL31736350 0.74 HCAR2 (0.58) HCAR2SMN1; SMN2RAB9ANPC1POLB
SCHEMBL4906894 0.72 HCAR2 (0.56) HCAR2SMN1; SMN2RAB9ANPC1POLB
SCHEMBL4906886 0.72 HCAR2 (0.56) HCAR2SMN1; SMN2RAB9ANPC1POLB
SCHEMBL28445923 0.72 ALDH1A1 (0.40) HCAR2SMN1; SMN2RAB9ANPC1POLB
SCHEMBL3667611 0.71 HCAR2 (0.50) HCAR2SMN1; SMN2RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
EP-2237669-A2 CHEMICAL COMPOUNDS Syngenta Limited (GB) 2010-10-13 EP disclosed
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
WO-2009081112-A2 CHEMICAL COMPOUNDS SYNGENTA LIMITED (GB) 2009-07-02 WO disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 HCAR2 3072/4885SMN1; SMN2 4831/4885RAB9A 1844/4885
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD HCAR2 3460/4885SMN1; SMN2 4683/4885RAB9A 391/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 HCAR2 3490/4885SMN1; SMN2 4814/4885RAB9A 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.